Drugs / Coppertone
Coppertone
Trials 28
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable28 trials | ||||||
| — | NCT02717351 | Mar 2016 | — | Bayer | Completed | No outcome recorded |
| — | NCT02717325 | Mar 2016 | — | Bayer | Completed | No outcome recorded |
| — | NCT02741466 | Mar 2016 | — | Bayer | Completed | No outcome recorded |
| — | NCT02739802 | Mar 2016 | — | Bayer | Completed | No outcome recorded |
| — | NCT02695303 | Feb 2016 | — | Bayer | Completed | No outcome recorded |
| — | NCT02682628 | Feb 2016 | — | Bayer | Completed | No outcome recorded |
| — | NCT02825030 | Dec 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02823509 | Dec 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02825017 | Dec 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02822313 | Nov → Dec 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02801929 | Nov 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02822300 | Nov 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02822248 | Nov → Dec 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02822274 | Nov → Dec 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02822261 | Nov → Dec 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02803099 | Nov 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02803047 | Nov 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02803034 | Nov 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02803060 | Nov 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02803008 | Oct → Nov 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02803021 | Oct → Nov 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02788162 | Oct 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02756988 | Oct 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02757014 | Oct 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02776501 | Sep 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02776852 | Aug 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02779842 | Jul → Aug 2015 | — | Bayer | Completed | No outcome recorded |
| — | NCT02779829 | Jul → Sep 2015 | — | Bayer | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-09-02 | Bayer | Bayer completes sale of iconic Coppertone™ brand to Beiersdorf bayer.com ↗ |
| 2019-05-13 | Bayer | Beiersdorf to acquire iconic Coppertone™ brand from Bayer bayer.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Coppertone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02822274 ↗ |
| Known as | BAY 987516 | “Coppertone (BAY 987516)” NCT02695303 ↗6“Coppertone (BAY 987516)” NCT02825030 ↗ “Coppertone (BAY987516)” NCT02803060 ↗ “Coppertone (BAY987516)” NCT02822261 ↗ “Coppertone (BAY987516)” NCT02803047 ↗ “Coppertone (BAY987516)” NCT02822248 ↗ “Coppertone (BAY987516)” NCT02803034 ↗ |
| Known as | BAY987517 | “Drug: Coppertone (BAY987517)” NCT02757014 ↗16“Coppertone (BAY 987517)” NCT02779842 ↗ “Coppertone (BAY 987517)” NCT02788162 ↗ “Coppertone (BAY 987517)” NCT02803099 ↗ “Coppertone (BAY 987517)” NCT02779829 ↗ “Coppertone (BAY 987517)” NCT02825017 ↗ “Coppertone (BAY 987517)” NCT02823509 ↗ “Coppertone (BAY 987517)” NCT02717351 ↗ “Coppertone (BAY987517)” NCT02717325 ↗ “Coppertone (BAY987517)” NCT02776852 ↗ “Coppertone (BAY987517)” NCT02741466 ↗ |
| Known as | BAY987518 | “Coppertone (BAY987518)” NCT02822313 ↗1“Coppertone (BAY987518)” NCT02801929 ↗ |
| Known as | BAY987521 | “Coppertone (BAY987521)” NCT02776501 ↗ |
| Known as | BAY987704 | “Coppertone (BAY987704)” NCT02756988 ↗ |
| Route | Topical | “The application of test material is 2 mg/cm\*2.” NCT02695303 ↗ |